Steven M. Dubinett

Steven M. Dubinett is a distinguished academic leader at the University of California Los Angeles (UCLA), serving as Dean of the School of Medicine and holding professorships in Medicine, Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology. His work is deeply integrated with key research centers including the UCLA Jonsson Comprehensive Cancer Center and the UCLA Clinical and Translational Science Institute, where he drives innovation in lung cancer research and translational medicine.

Dubinett earned his medical degree from Rutgers New Jersey Medical School in 1980, followed by an internship and residency in Internal Medicine at University Hospital and UCLA. He completed specialized fellowships in Pulmonary Medicine at Massachusetts General Hospital and in Tumor Immunology at Harvard Medical School, establishing the foundation for his career at the intersection of pulmonary medicine and cancer research.

Dr. Dubinett's research program is centered on the pathogenesis of lung cancer, with particular emphasis on translational approaches to understanding immunobiology, tumor microenvironment dynamics, and mechanisms of epithelial-mesenchymal transition in human non-small cell lung cancer. His laboratory has made seminal contributions to understanding how chronic inflammation drives lung carcinogenesis and how these insights can be translated into novel therapeutic strategies. His work bridges molecular mechanisms with clinical applications, focusing on identifying targets for lung cancer interception and prevention.

Analysis of Dr. Dubinett's recent publications (2023-2025) reveals a sophisticated integration of multi-omics approaches with spatial analysis to understand lung adenocarcinoma evolution. His research increasingly focuses on tumor heterogeneity, immune microenvironment characterization, and innovative immunotherapeutic approaches including dendritic cell vaccines and engineered immune cells. A significant portion of his work addresses mechanisms of immunotherapy resistance and strategies to overcome it through combination approaches.

Among his numerous accolades, Dr. Dubinett received the prestigious William S. Middleton Award from the U.S. Department of Veterans Affairs in 2019, the American Thoracic Society Recognition Award for Scientific Accomplishments in 2008, and the Stanley Blatt Award for Lung Cancer Research in 1999. His work has been consistently recognized by the American Lung Association through multiple awards spanning his career.

Dr. Dubinett has secured substantial research funding throughout his career, including NIH grants and institutional support that has enabled his team to pursue cutting-edge approaches to lung cancer diagnosis and treatment. His leadership extends to national advisory roles, including chairing the FDA Cellular, Tissue and Gene Therapies Advisory Committee, and representing UCLA in international research collaborations with the Chinese Academy of Sciences. He has mentored numerous physician-scientists who have gone on to establish their own research programs in oncology and pulmonary medicine.

Dr. Dubinett leads a multidisciplinary research team within the UCLA Jonsson Comprehensive Cancer Center focused on translating basic discoveries into clinical applications. His laboratory employs advanced techniques in molecular biology, immunology, and systems biology to investigate the molecular mechanisms of lung cancer development and progression. Current research directions include developing non-invasive diagnostic approaches using liquid biopsies, understanding the evolution of premalignant lesions, and developing novel immunotherapeutic strategies to enhance T-cell responses against lung cancer.